Cytonics Corporation, a clinical-stage biotech company, completed a financing round raising $4.8 million from about 1,500 investments, including 900 new investors. This brings their total capital raised to $47 million and expands their investor base to around 8,000. The funds will support further development of CYT-108, an engineered biologic targeting cartilage degradation in osteoarthritis. The company plans to advance regulatory and clinical steps toward a Phase 1b/2a study, with potential future financing campaigns planned after key milestones.
J.Jill reported strong Q2 earnings, beating estimates with $1.24 EPS and $154.83M revenue, driven by sales growth and direct sales increase. Following this, BTIG raised its price target to $25, suggesting a 15.74% upside. The company also raised its ...
BMO Capital Markets initiated coverage of Lululemon Athletica with an Underperform rating and a $70 price target, citing weakening demand in key markets and margin pressures. This follows a 4% revenue decline in Q2 and a reduced full-year forecast. M...
Core & Main reported strong Q2 earnings with EPS of $0.94, surpassing the $0.92 analyst estimate and showing an 8% increase year-over-year. Revenue reached $2.15 billion, slightly above the $2.14 billion expected, supported by robust municipal infras...
Korn Ferry reported strong Q1 results with earnings per share of $1.43 and revenue of $756.5 million, both exceeding analyst expectations and marking continued growth. Despite this, the stock fell due to conservative guidance for the next quarter, wh...
SailPoint reported Q2 2026 earnings with revenue of $308.81 million, slightly below estimates but up 17% year-over-year. Adjusted EPS of $0.09 beat analyst expectations by 12.5%, reflecting improved profitability. The company showed strong subscripti...
